XY 1029Alternative Names: XY1029
Latest Information Update: 03 Mar 2010
At a glance
- Originator Xytis
- Mechanism of Action GABA A receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Anxiety disorders
Most Recent Events
- 03 Mar 2010 Discontinued - Preclinical for Anxiety disorders in Switzerland (unspecified route)
- 30 Mar 2006 Preclinical trials in Anxiety disorders in Switzerland (unspecified route)